US2992970A - Aqueous sorbitol enema solution and method of using same - Google Patents
Aqueous sorbitol enema solution and method of using same Download PDFInfo
- Publication number
- US2992970A US2992970A US685430A US68543057A US2992970A US 2992970 A US2992970 A US 2992970A US 685430 A US685430 A US 685430A US 68543057 A US68543057 A US 68543057A US 2992970 A US2992970 A US 2992970A
- Authority
- US
- United States
- Prior art keywords
- sorbitol
- solution
- enema
- potassium
- aqueous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 title claims description 24
- 239000000600 sorbitol Substances 0.000 title claims description 24
- 241000792859 Enema Species 0.000 title claims description 23
- 239000007920 enema Substances 0.000 title claims description 23
- 229940095399 enema Drugs 0.000 title claims description 22
- 238000000034 method Methods 0.000 title description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000012153 distilled water Substances 0.000 claims description 9
- 229960000878 docusate sodium Drugs 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- CTTJWXVQRJUJQW-UHFFFAOYSA-N 2,2-dioctyl-3-sulfobutanedioic acid Chemical compound CCCCCCCCC(C(O)=O)(C(C(O)=O)S(O)(=O)=O)CCCCCCCC CTTJWXVQRJUJQW-UHFFFAOYSA-N 0.000 claims description 5
- 231100000252 nontoxic Toxicity 0.000 claims description 5
- 230000003000 nontoxic effect Effects 0.000 claims description 5
- 239000000243 solution Substances 0.000 description 32
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 23
- SRQKEEPVRWNRQZ-UHFFFAOYSA-N 1,4-bis(2-ethylhexoxy)-1,4-dioxobutane-2-sulfonic acid;potassium Chemical group [K].CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC SRQKEEPVRWNRQZ-UHFFFAOYSA-N 0.000 description 11
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 7
- 235000010235 potassium benzoate Nutrition 0.000 description 7
- 239000004300 potassium benzoate Substances 0.000 description 7
- 229940103091 potassium benzoate Drugs 0.000 description 7
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 5
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 5
- 239000000203 mixture Substances 0.000 description 4
- 239000005711 Benzoic acid Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 235000010233 benzoic acid Nutrition 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
- 229960002216 methylparaben Drugs 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 3
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
- 206010062237 Renal impairment Diseases 0.000 description 2
- 239000004902 Softening Agent Substances 0.000 description 2
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 2
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 239000013530 defoamer Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001417524 Pomacanthidae Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- YHAIUSTWZPMYGG-UHFFFAOYSA-L disodium;2,2-dioctyl-3-sulfobutanedioate Chemical compound [Na+].[Na+].CCCCCCCCC(C([O-])=O)(C(C([O-])=O)S(O)(=O)=O)CCCCCCCC YHAIUSTWZPMYGG-UHFFFAOYSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 230000001189 fecal softening effect Effects 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 208000027692 gas pain Diseases 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 235000014659 low sodium diet Nutrition 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000008149 soap solution Substances 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
Definitions
- This invention relates to an aqueous enema solution, and particularly to a solution which is safe for use in cardiac and diabetic patients.
- Enemas are used to evacuate the bowel of patients or to prepare patients for sigmoidoscopic examination.
- a large volume of soap solution has usually been used. The large volume causes discomfort to the patient and the soap often irritates the mucous membrane.
- a relatively small volume of hypertonic sodium phosphate solution has been used.
- Such concentrated salt solutions may burn or sting if fissures, open hemorrhoids, or other anal pathologies exist.
- Other constituents, which may increase the effectiveness of the enema solutions have only limited solubility in the concentrated salt solutions.
- a dangerous amount of sodium may be absorbed by patients, who because of heart conditions or renal impairment are on a low-sodium diet.
- the object of this invention is to provide an inexpensive, effective, evacuant enema solution having a minimum of contraindications.
- Another object of the invention is to provide an effective, sodium-free enema solution.
- Another object of the invention is to provide an enema solution which will not burn or irritate the rectal mucosa, or openings therein.
- the enema solution of this invention does not cause irritation or burning of fissures or other open places in the rectal mucosa. Moreover, it may be used by patients with cardiac or renal impairment and in diabetic patients. Adequate quantities of a fecal softening agent, such as a salt of dioctyl sulfosuccinic acid, and of a preservative, such as a mixture of methyl and propyl parabens or potassium benzoate, can be dissolved in the enema solution.
- a fecal softening agent such as a salt of dioctyl sulfosuccinic acid
- a preservative such as a mixture of methyl and propyl parabens or potassium benzoate
- the preferred softening agent is potassium dioctyl sulfosuccinate. Concentrations of 0.03 to 0.5 are effective, with 0.1% being preferred. The higher concentrations of potassium dioctyl sulfosuccinate are used for more dilute sorbitol solutions and the lower concentrations for more concentrated solutions.
- this enema solution forms a stable foam.
- This foam interferes with preparation and filling of the solution.
- the foam interferes with rectal examination, or may cause the patient to have gas pains. It may therefore be desirable to add a defoamer, preferably of the silicone type. Methylpolysiloxane has been found particularly effective in concentrations of 0.2 to ppm.
- the enema solution of this invention may be sterilized by heat. Preferably, however, it contains a preservative, such as 0.03 to 0.3% of a salt of benzoic acid. Potassium benzoate is preferred but other benzoates may also be used. Parahydroxy benzoates (parabens) may also be used. A combination of 0.15% methyl para- 2,992,970 Patented July 18, 1961 Example 1 Sorbitol kilograms 25 Potassium dioctyl sulfosuccinate grams Potassium benzoate do 100 istilled Water, quantity to makelOO liters.
- Stoichiometn'c quantities of benzoic acid and potassium hydroxide are dissolved in 40 liters of water giving a pH of approximately 5.3. The desired amount of sorbitol is then added as the 70% solution. The potassium dioctyl sulfosuccinate is dissolved in water to form an 0.5% solution and added to the mixture. Distilled water is added to the final desired volume of 100 liters.
- Sorbitol, dioctyl sulfosuccinate and sodium benzoate are dissolved in 40 liters of water and the pH adjusted to 5.3.
- the methylpolysiloxane solution is added and distilled water added to a final volume of 100 liters.
- Example 4 Sorbitol kilograms 20 Potassium dioctyl sulfosuccinate grams 150 Potassium benzoate do 500 Methylpolysiloxane do 1 Distilled Water, quantity to make 100 liters.
- the solution of sorbitol, dioctyl sulfosuccinate and potassium benzoate is made up as in Example 1.
- the methylpolysiloxane is added as an emulsion in a nontoxic emulsifying agent.
- the mixture is diluted to 100 liters with distilled water.
- An aqueous evacuant enema solution containing 15 to 35% by weight of sorbitol and a nontoxic salt of dioctyl sulfosuccinic acid in distilled water.
- a sodium-free, aqueous evacuant enema solution comprising: 15 to 35 sorbitol; 0.03 to 0.5 potassium dioctyl sulfosuccinate; .2. to 10 ppm. methylpolysiloxane; and 0.03 to 0.3% potassium benzoate.
- An aqueous evacuant enema solution comprising:
- a sodium-free, aqueous evacuant enema solution comprising: about 25 sorbitol; 0.1% potassium dioctyl sulfosuccinate; 0.1% potassium benzoate; 10 ppm. methylpolysiloxane; and having a pH of substantially 5.3.
- An aqueous evacuant enema solution comprising: about 25% sorbitol; 0.1% of a nontoxic salt of dioctyl sulfosuccinic acid; and having a pH of substantially 5.
- An aqueous evacuant enema solution comprising: 15 to 35% sorbitol; 0.03 to 0.5% potassium dioctyl sulfosuccinate; 0.2 to 10 p.p.m. of a methylpolysiloxane defoamer; 0.05 to 0.25% methyl parahydroxybenzoate and 0.01 to 0.05% propyl parahydroxybenzoate.
- a sodium-free, aqueous evacuant enema solution comprising: about 25% sorbitol; 0.1% potassium dioctyl sulfosuccinate; 0.15% methyl parahydroxybenzoate; 0.03% propyl parahydroxybenzoate; 10 ppm. methylpolysiloxane; and having a pH of substantially. 5.3.
- the process of evacuating a human patient which comprises introducing into the rectum of said patient an aqueous solution containing from 15 to 35 sorbitol.
- Wilson J.A.M.A., vol. 158, No. 4, pages 261-263, May 28, 1955.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
Description
United States Patent D 2,992,970 AQUEOUS SORBITOL ENEMA SOLUTION AND METHOD OF USING SAME Victor H. Baptist, Burbank, and Arthur Cherkin, Los
'Angeles, Calif., assignors to Don Baxter, Inc., Glendale, Calif., a corporation of Nevada No Drawing. Filed Sept. 23, 1957, Ser. No. 685,430
10 Claims. (Cl. 167--50) This invention relates to an aqueous enema solution, and particularly to a solution which is safe for use in cardiac and diabetic patients.
Enemas are used to evacuate the bowel of patients or to prepare patients for sigmoidoscopic examination. In the past, a large volume of soap solution has usually been used. The large volume causes discomfort to the patient and the soap often irritates the mucous membrane. More recently, a relatively small volume of hypertonic sodium phosphate solution has been used. Such concentrated salt solutions may burn or sting if fissures, open hemorrhoids, or other anal pathologies exist. Other constituents, which may increase the effectiveness of the enema solutions, have only limited solubility in the concentrated salt solutions. Moreover, a dangerous amount of sodium may be absorbed by patients, who because of heart conditions or renal impairment are on a low-sodium diet.
The object of this invention is to provide an inexpensive, effective, evacuant enema solution having a minimum of contraindications.
Another object of the invention is to provide an effective, sodium-free enema solution.
Another object of the invention is to provide an enema solution which will not burn or irritate the rectal mucosa, or openings therein.
We have found that a 25% (weight/volume) sorbitol solution is efiective as an evacuant enema. Concentrations of sorbitol as high as 40% are effective. Concentrations of sorbitol as low as 15% may be used. The solutions of 35 to 40% tend to be sticky, however, and this causes diificulty during sigmoidoscopic examination. The preferred range is therefore l5-35% by weight of sorbitol. One hundred twenty cc. of solution is usually used, although the volume may vary from 100 to 140 cc.
The enema solution of this invention does not cause irritation or burning of fissures or other open places in the rectal mucosa. Moreover, it may be used by patients with cardiac or renal impairment and in diabetic patients. Adequate quantities of a fecal softening agent, such as a salt of dioctyl sulfosuccinic acid, and of a preservative, such as a mixture of methyl and propyl parabens or potassium benzoate, can be dissolved in the enema solution.
The preferred softening agent is potassium dioctyl sulfosuccinate. Concentrations of 0.03 to 0.5 are effective, with 0.1% being preferred. The higher concentrations of potassium dioctyl sulfosuccinate are used for more dilute sorbitol solutions and the lower concentrations for more concentrated solutions.
Under some conditions this enema solution forms a stable foam. This foam interferes with preparation and filling of the solution. Also, when the enema is administered to a patient, the foam interferes with rectal examination, or may cause the patient to have gas pains. It may therefore be desirable to add a defoamer, preferably of the silicone type. Methylpolysiloxane has been found particularly effective in concentrations of 0.2 to ppm.
The enema solution of this invention may be sterilized by heat. Preferably, however, it contains a preservative, such as 0.03 to 0.3% of a salt of benzoic acid. Potassium benzoate is preferred but other benzoates may also be used. Parahydroxy benzoates (parabens) may also be used. A combination of 0.15% methyl para- 2,992,970 Patented July 18, 1961 Example 1 Sorbitol kilograms 25 Potassium dioctyl sulfosuccinate grams Potassium benzoate do 100 istilled Water, quantity to makelOO liters.
Stoichiometn'c quantities of benzoic acid and potassium hydroxide are dissolved in 40 liters of water giving a pH of approximately 5.3. The desired amount of sorbitol is then added as the 70% solution. The potassium dioctyl sulfosuccinate is dissolved in water to form an 0.5% solution and added to the mixture. Distilled water is added to the final desired volume of 100 liters.
Example 2 Sorbitol kilograms 40 Potassium dioctyl sulfosuccinate grams 50 Methyl parahydroxybenzoate do Propyl parahydroxybenzoate do 30 Distilled water, quantity to make 100 liters.
Approximately 50 liters of water are placed in a tank, heated, and the methyl and propyl parahydroxybenzoates dissolved. The sorbitol is then added as the 70% solution. The potassium dioctyl sulfosuccinate is dissolved in water to form an 0.5 solution, and added to the mixture. The pH is adjusted to 5.3 with benzoic acid.
Example 3 Sorbitol kilograms 15 Sodium dioctyl sulfosuccinate "grams" 500 Sodium benzoate do 100 30% solution of methylpolysiloxane do 34 Distilled water, quantity to make 100 liters.
Sorbitol, dioctyl sulfosuccinate and sodium benzoate are dissolved in 40 liters of water and the pH adjusted to 5.3. The methylpolysiloxane solution is added and distilled water added to a final volume of 100 liters.
Example 4 Sorbitol kilograms 20 Potassium dioctyl sulfosuccinate grams 150 Potassium benzoate do 500 Methylpolysiloxane do 1 Distilled Water, quantity to make 100 liters.
The solution of sorbitol, dioctyl sulfosuccinate and potassium benzoate is made up as in Example 1. The methylpolysiloxane is added as an emulsion in a nontoxic emulsifying agent. The mixture is diluted to 100 liters with distilled water.
We claim:
1. An aqueous evacuant enema solution containing 15 to 35% by weight of sorbitol and a nontoxic salt of dioctyl sulfosuccinic acid in distilled water.
2. A sodium-free, aqueous evacuant enema solution comprising: 15 to 35 sorbitol; 0.03 to 0.5 potassium dioctyl sulfosuccinate; .2. to 10 ppm. methylpolysiloxane; and 0.03 to 0.3% potassium benzoate.
3. An aqueous evacuant enema solution comprising:
sorbitol; potassium dioetyl sulfosuccinate; a methylpolysiloxane; and a preservative.
4. A sodium-free, aqueous evacuant enema solution comprising: about 25 sorbitol; 0.1% potassium dioctyl sulfosuccinate; 0.1% potassium benzoate; 10 ppm. methylpolysiloxane; and having a pH of substantially 5.3.'
5. An aqueous evacuant enema solution comprising: about 25% sorbitol; 0.1% of a nontoxic salt of dioctyl sulfosuccinic acid; and having a pH of substantially 5. 3.
6. An aqueous evacuant enema solution comprising: 15 to 35% sorbitol; 0.03 to 0.5% potassium dioctyl sulfosuccinate; 0.2 to 10 p.p.m. of a methylpolysiloxane defoamer; 0.05 to 0.25% methyl parahydroxybenzoate and 0.01 to 0.05% propyl parahydroxybenzoate.
7. A sodium-free, aqueous evacuant enema solution comprising: about 25% sorbitol; 0.1% potassium dioctyl sulfosuccinate; 0.15% methyl parahydroxybenzoate; 0.03% propyl parahydroxybenzoate; 10 ppm. methylpolysiloxane; and having a pH of substantially. 5.3.
8. A ready-to-use, aqueous evacuant enema solution containing 15 to 35% by weight of sorbitol in distilled water and a nontoxic salt of dioctyl sulfosuccinic acid, said salt of sulfosuccinic acid being present in a concen- 10. The process of evacuating a human patient which comprises introducing into the rectum of said patient an aqueous solution containing from 15 to 35 sorbitol.
References Cited in the file of this patent UNITED STATES PATENTS I Hardie Oct. 25,1955
OTHER REFERENCES Chem. Abst., vol. 43, page 6815b, 1949.
Wilson: J.A.M.A., vol. 158, No. 4, pages 261-263, May 28, 1955.
Modern Drug Encyclopedia, 6th Ed., pages 436 and 437, 1955.
U.S. Dispensatoiy, 25th Ed., pages 1764, 1302 and
Claims (1)
1. AN AQUEOUS EVACUANT ENEMA SOLUTION CONTAINING 15 TO 35% BY WEIGHT OF SORBITOL AND A NONTOXIC SALT OF DIOCTYL SULFOSUCCINIC ACID IN DISTILLED WATER.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US685430A US2992970A (en) | 1957-09-23 | 1957-09-23 | Aqueous sorbitol enema solution and method of using same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US685430A US2992970A (en) | 1957-09-23 | 1957-09-23 | Aqueous sorbitol enema solution and method of using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US2992970A true US2992970A (en) | 1961-07-18 |
Family
ID=24752177
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US685430A Expired - Lifetime US2992970A (en) | 1957-09-23 | 1957-09-23 | Aqueous sorbitol enema solution and method of using same |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US2992970A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3275509A (en) * | 1963-04-24 | 1966-09-27 | Robert L Rowan | Method for treating intestinal disorders with a silicone composition enema |
| US4201706A (en) * | 1978-09-22 | 1980-05-06 | Burton, Parsons & Company, Inc. | Treatment of corneal edema |
| US20140107197A1 (en) * | 2007-12-07 | 2014-04-17 | Ferring International Center S.A. | Pharmaceutical composition |
| EP2865371A1 (en) | 2013-10-22 | 2015-04-29 | Disphar International B.V. | Fast dissolving granules |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2721825A (en) * | 1952-08-11 | 1955-10-25 | Cutter Lab | Irrigation fluid for cystoscopy and transurethral prostatectomy |
-
1957
- 1957-09-23 US US685430A patent/US2992970A/en not_active Expired - Lifetime
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2721825A (en) * | 1952-08-11 | 1955-10-25 | Cutter Lab | Irrigation fluid for cystoscopy and transurethral prostatectomy |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3275509A (en) * | 1963-04-24 | 1966-09-27 | Robert L Rowan | Method for treating intestinal disorders with a silicone composition enema |
| US4201706A (en) * | 1978-09-22 | 1980-05-06 | Burton, Parsons & Company, Inc. | Treatment of corneal edema |
| US20140107197A1 (en) * | 2007-12-07 | 2014-04-17 | Ferring International Center S.A. | Pharmaceutical composition |
| EP2865371A1 (en) | 2013-10-22 | 2015-04-29 | Disphar International B.V. | Fast dissolving granules |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Foss et al. | Oral methyltestosterone and jaundice | |
| US2992970A (en) | Aqueous sorbitol enema solution and method of using same | |
| Davies | The history of syphilis in Uganda | |
| FRIEDMAN et al. | THE HYPERTENSIVE EFFECT OF COMPOUND FACETATE (17-OH-CORTICOSTERONE-21-ACETATE) IN THfi RAT | |
| McGeorge et al. | Observations on the properties of S-methyl iso-thiourea sulphate, with particular reference to the circulatory effects | |
| Smith | Severe anaphylactic reaction after a soap enema | |
| Lauber et al. | Toxicity of the mucigogue, eugenol, administered by stomach tube to dogs | |
| Noble et al. | Lithosperm-Like Action of Certain Quinones | |
| Seelig | Localized gangrene following the hypodermic administration of calcium chlorid | |
| Vokoun | Linseed oil dermatitis | |
| Hahnemann | The lesser writings of Samuel Hahnemann | |
| ROBINSON et al. | THE TREATMENT OF ACUTE ALCOHOLISM: WITH TEN PER CENT CARBON DIOXIDE AND NINETY PER CENT OXYGEN INHALATION | |
| Chopra et al. | Carbon Tetrachloride in Pharmacology and Therapeutics | |
| US2486937A (en) | Digitalis therapy | |
| Goodwin | The Hospital treatment of diseases of the heart and lungs | |
| Milch | Local anesthesia in the treatment of visceral and serous pains | |
| Morlock | Chronic Pneumothorax Treated by Intra-pleural Injection of Silver Nitrate | |
| Upcott | chloroform. Under hedonal, although perception | |
| Heard | CLINICAL EXPERIENCES WITH AVERTIN ANÆSTHESIA | |
| Stammers | Lymphogranuloma Inguinale (Tropical Bubo) | |
| WILDER | III. APPLICATION IN INTERNAL MEDICINE | |
| Lees | Pancreatic Glycerine | |
| from Pethidine | Current opics, Etc. | |
| NEAL et al. | EFFECT OF ACTH, CORTISONE, AND DOCA® ON SURVIVAL OF BURNED RAT | |
| Ehrlich et al. | " 606" in Theory and Practice |